RMT-Epigenomex, Inc.
Reducing Time & Cost for Drug Discovery

RMT has assembled a strong management team with deep and complementary experience in key areas including science, legal, finance and start-ups

Management Team

JOHN ALETTA - Chief Scientific Officer    

In 1997, John’s laboratory was the first to demonstrate a requirement for specific protein methylation in the cellular development of neuronal model systems. As a faculty member in the Department of Pharmacology and Toxicology at the University at Buffalo School of Medicine & Biomedical Sciences, John spent 17 years teaching and contributing peer-reviewed research in the fields of post-translational protein modification and methylation biology.


John received his doctoral degree while working in the Center for Neurobiology and Behavior at the Columbia University College of Physicians and Surgeons in New York City in 1984.  In addition, he earned two Masters level degrees in Pharmacology at Columbia University (M.A. 1980 and M.Phil. 1981) prior to completing the Ph.D. Following postdoctoral training in Cellular and Molecular Biology in the laboratory of Lloyd A. Greene at New York University, Dr. Aletta returned to the Columbia College of Physicians and Surgeons as a faculty member in the Department of Pathology. In 1990 he came to Buffalo, New York to join the faculty at the University at Buffalo School of Medicine.


John was a Co-Founder and the Director of Research at CH3 BioSystems, which through his longstanding professional contacts has developed a global network of manufacturing and distribution partners.

email: jmaletta@rmt-epigenomex.com

JOE HARRIS - President and Chief Executive Officer    

Joe has over 25 years of experience in mergers and acquisition and venture capital, and has a diverse background in the health industry, accounting, and law.  He formerly served as Senior Vice President and Director of Corporate Strategy and Development for SmithKline Beecham, currently Glaxo SmithKline, a multi-billion dollar global research based pharmaceutical company. During his tenure in that role, he analyzed, planned and executed several strategic transactions for the company totaling in excess of $2 billion, including acquisitions, divestitures and joint ventures.


Prior to his position with SmithKline Beecham, Joe served as Managing Director of Business Development for Eastman Kodak Company, a global manufacturer and marketer of traditional and digital imaging products and services. In this position, he planned and managed over 45 strategic transactions, including acquisitions, divestitures, joint ventures and licensing transactions, totaling in excess of $10 billion.


Mr. Harris has also served in senior management positions with companies that manufacture and market electronics and medical devices. Mr. Harris practiced as a certified public accountant with the accounting firm of Coopers & Lybrand and as an attorney with The MacKenzie Law Firm.


Mr. Harris holds a BS in accounting, an MBA in finance and a law degree from Syracuse University. He served on the Boards of Diomed, Inc., a publicly traded medical device company, and Pacific Health Laboratories, Inc., a publicly traded nutritional products company, and was a partner and fund manager of Trillium Lakefront Partners, III, a technology venture capital fund that focuses on technologies in life sciences, photonics, imaging and nano-technology.

email: jharris@rmt-epigenomex.com

STEVE DONDERO – Chief Operating Officer and Chief Financial Officer

Steve is an investment professional with 25 years of experience in private equity, capital markets and early-stage investing. Steve is currently on the Advisory Committee for Star Mountain Capital, a Small Business Investment Company (SBIC) fund-of-funds. Mr. Dondero was previously a Partner and Investment Advisory Committee member at Aegis Capital Group LLC. He has been a private venture capital investor and executed numerous direct venture investments across industries including technology, media and entertainment, software and healthcare. In addition to his investment experience, Mr. Dondero has advised companies on capital markets trends and opportunities as well as merger and acquisition activities. He has given presentations at industry events and published reports on a wide array of sectors and companies.


Mr. Dondero was a capital markets expert for BMO Capital Markets’ leveraged finance group providing corporate clients with capital raising and structuring advice. Formerly, Mr. Dondero was the Head of High Yield and Distressed Research at BMO.


Mr. Dondero holds an MBA in finance and international business from Fordham University and a Bachelor of Engineering degree in Electrical Engineering from Stevens Institute of Technology.

email: sdondero@rmt-epigenomex.com